Patheon's Mullen: Drug Price Debate Could Shape Pharma's Future
Commercial Product Supply
Author: Frank Vinluan
Tuesday, October 27, 2015
Even as Patheon CEO Jim Mullen sees promise in the scientific advances made in drug development, he says many of the pharmaceutical industry’s challenges ahead are economic.
With pharmacoeconomics - the comparison of the economic value of therapies - playing a greater role in how insurance companies cover medicines, it's critical for companies to think about reimbursement early on, Mullen said, speaking at the annual meeting of the North Carolina Biosciences Organization (NCBIO) last week.
Please complete the short form below to download this whitepaper.